Vectura Share Discussion Threads

[base7] 01/12/2020 18:31

If it has been written off by Vec as it wasn’t considered viable & 2 former senior employees believe it has a future & have Forbes a company with a known entrepreneur in this space & have convinced investors that it was worth their stomping up $40mill -I don’t see any downside for us .We will be ,presumably,well paid for our ongoing development work & we will share in the upside by receive royalties ,should a product ever get to market.Obviously the potential will never be as substantial as owning it all but then we would be carrying 100% of the risk & we know how it feels when a major prospective product is shelved ,eg Flutiform in the USA .

[best1467] 01/12/2020 18:07

Popper joe that did cross my mind as to whether it could reserve some of the write downs on the Research and development which I would imagine would have been substantial but do confess I’m not an expert as to if it’s possible but on the basis they continue to be carried on the balance sheet it may be possible

[alexchry] 01/12/2020 16:51

Hikma down almost 5%, hope it has nothing to do with Advair approval or lack of it.

[polaris] 01/12/2020 15:04

@Popper Joe - it's been a while since i really looked at that side of things. As i understand it, the original IP value would still be completely written off. This agreement is then a pure contract for services, which may have additional future value embedded / carried - a new intangible asset, no?

edit
Just looked back - it's been a good 2 years since I last mentioned VR588. June 2018 (post 7362 at the bottom in the discontinued developments)...there were a few posts about it and then some all the way back to 2014.

[popper joe] 01/12/2020 14:55

Paul, with regard to yesterday's announcement about VR588: Am I right in thinking that this is one of the pipeline drugs that was dropped and its future value written-off, thereby contributing to our ongoing losses due to write-downs? If so, any views on the impact of this effectively being resurrected?

[cityfarmer] 01/12/2020 14:47

How times have changed we (SKP) sold this to Pacira when we had too many irons in the fire and couldn’t finance the progression now we seem to have pots of money and nothing to really spend it on. If only we had held onto to it what would we be worth today …? Pacira annual sales almost = to our market cap !!!!

[popper joe] 01/12/2020 14:02

Whilst we sit and wait to see if GSK finally accept their punishment or choose to carry on the bad fight, this might ease our collective nerves a little. Based on everything that has been stated and argued in the original and the appeal trial, I am not sure there are many grounds on which GSK can petition the Supreme Court.

[a1ord53] 01/12/2020 11:07

Last Petition in 2017 to usa supreme court by GSK DENIED :


DATE PROCEEDINGS AND ORDERS
Feb 09 2017 Application (16A806) to extend the time to file a petition for a writ of certiorari from February 21, 2017 to March 23, 2017, submitted to Justice Kagan.
Feb 10 2017 Application (16A806) granted by Justice Kagan extending the time to file until March 23, 2017.
Mar 23 2017 Petition for a writ of certiorari filed. (Response due April 27, 2017)
Apr 19 2017 Order extending time to file response to petition to and including May 30, 2017.
Apr 27 2017 Brief amicus curiae of Pharmaceutical Research and Manufacturers of America filed.
Apr 27 2017 Brief amicus curiae of The Chamber of Commerce of The United States of America filed.
May 30 2017 Brief of respondents M. M. ex rel, Meyers, et al. in opposition filed.
Jun 14 2017 DISTRIBUTED for Conference of September 25, 2017.
Jun 15 2017 Reply of petitioner GlaxoSmithKline LLC filed. (Distributed)
Sep 06 2017 Supplemental brief of petitioner Glaxo Smith Kline LLC filed. (Distributed)
Sep 11 2017 Supplemental brief of respondents M. M., et al. filed. (Distributed)
Oct 02 2017 Petition DENIED.

[ambiorix1] 01/12/2020 09:09

Kinaset Therapeutics Launches with a $40M Series A Financing to Develop Novel
Therapeutics for Respiratory Diseases and an Exclusive Global License Agreement
with Vectura Group for KN-002 (VR588), a Novel Anti-Inflammatory
• Founded by serial bioentrepreneur Robert Clarke, Ph.D., with Roger
Heerman, MBA, and Frazer Morgan, the executive leadership has over
sixty-five combined years of biopharma experience and significant expertise
in respiratory drug development and commercialization
• Venture syndicate with deep experience investing in respiratory and
inflammatory diseases includes co-leads 5AM Ventures and Atlas Venture,
with participation from leading European investor Gimv
• Agreements with Vectura include an exclusive global license to KN-002, a
novel pan-JAK inhibitor, as well as a services agreement to support clinical
trial supply and CMC activities leveraging Vectura’s CDMO leadership in
the field of inhaled therapeutics
• Company’s lead program is initially focused on the unmet need in
eosinophilic and non-eosinophilic severe asthma patients with a Phase 1/1b
study planned in 1H 2021
MEDFIELD, MA, November 30, 2020 (GLOBE NEWSWIRE) — Kinaset Therapeutics, Inc.
(“Kinaset̶1; or the “Company”;), a newly-founded biopharmaceutical company, today announced a
$40 million Series A financing with a blue-chip investor syndicate of 5AM Ventures, Atlas
Venture, and Gimv. The Company also announced an exclusive global in-license and services
agreement with Vectura Group plc (LSE: VEC) (“Vectura̶1;) to develop and commercialize KN002 (formerly known as VR588), a novel, inhaled small-molecule pan-JAK inhibitor, for the
treatment of eosinophilic and non-eosinophilic severe asthma. A Phase 1/1b clinical trial in
healthy volunteers and patients is poised to begin in the first half of 2021.
Kinaset is led by an experienced management team and Board of Directors with strong
backgrounds in the development of respiratory therapeutics. The company is led by Chief
Executive Officer Robert Clarke (formerly Pulmatrix, AIR/Alkermes), Chief Business Officer
Roger Heerman (GlaxoSmithKline, Vectura), and Chief Development Officer Frazer Morgan
(Vectura, 3M), each of whom has over 20 years of experience in the industry. Thomas B. King
(Alexza, Vivus), Chairman of the Board, is joined on the Kinaset Board of Directors by founding
investors Jamil Beg (5AM), Kevin Bitterman (Atlas), and Bram Vanparys (Gimv).
Kinaset is responsible for the overall development and commercialization of KN-002, with
Vectura providing formulation development expertise and manufacturing of clinical trial

[peddlers] 30/11/2020 18:47

Yeah, I just thought myself, someone is taking the P

[justiceforthemany] 30/11/2020 16:38

UT gone the other way today.
Comical.
These markets are totally UNregulated.

[alexchry] 30/11/2020 14:55

Vectura had VR588 and plenty of cash but decided not to go ahead with any further development, not sure what has changed to persuade this small company that it's worth investing in its development.

[diesel] 30/11/2020 14:37

Hope you’re right Base, but both 588 and 325 have been adopted by tiny companies both with links to Ventura, if these were promising candidates I would have expected a more substantial interest.

[base7] 30/11/2020 12:56

Kinaset is apparently a start up which received $1.5million in initial funding in Aug 2020 & has a very experienced senior management team, including Frazer Morgan ( ex Vectura) as CDO .They have today raised $40mill series A funding for the development of VR588 & it is fair to assume that a reasonable % of those funds raised will be coming to Vec in respect of work to be done to take the project to the next stage.
What is not to like about a deal which will generate rvenue, has no downside & if VR588 is succesful , eventually , we will share in the upside , allbeit at a lower level but without taking onboard all the risk.
My view is that todays announcement is more significant than it may have first appeared & will hopefully help the continued recovery in our SP

[fhmktg] 30/11/2020 12:44

https://erj.ersjournals.com/content/early/2020/07/02/13993003.01919-2020Discussion about JAK inhibitors for Covid19

[fhmktg] 30/11/2020 09:34

Interesting comment in the RNS that this group of chemicals have interest in the treatment of severe inflammation responses.....Covid19 possible interest as a dexamethazone type?

[base7] 30/11/2020 08:06

Although no revenue was attributed to this mornings RNS my view is that it represents a milestone in our CDMO business & that while the potential revenue may be significant, we will be paid for all work done in trying to bring the product to market, thereby minimising our downside & generating revenue & profits

[polaris] 28/11/2020 12:44

@peddlers - could be an end of period rebalancing then from some larger group of funds. Strange for end of November, but not impossible.

[peddlers] 27/11/2020 19:46

Polaris - I've noticed quite a few of my stocks have a large UT well above the spread.
Strange.

[polaris] 27/11/2020 18:35

Interesting uncross trade today. Quite large and well above spread...

[boadicea] 26/11/2020 15:20

One would normally expect to see a a counter-trade at the same or similar price to one of that size. Possibly held until after hours (17:15)?

[peddlers] 26/11/2020 14:09

Dare I say the rate of descent is starting to slow down

[babbler] 26/11/2020 10:58

1.66m trade??

[justiceforthemany] 25/11/2020 14:43

The chances of a substantial capital return to shareholders and M&A are surely very high here.

[alexchry] 24/11/2020 14:30

Nearly four years late, unfortunately.